Lenire Biosciences Completes License Agreement with University College London for VSN16R, A Novel Clinical Candidate Treatment for Fragile X Syndrome
June 16, 2022 08:59 ET
|
Lenire Biosciences
SAN DIEGO, June 16, 2022 (GLOBE NEWSWIRE) -- Lenire Biosciences Inc., a biopharmaceutical company developing novel treatments for Fragile X Syndrome (FXS) and related disorders, today announced that...
Green Nexus is the First Authorized United States Distributor of Barneys Farm Seeds
February 08, 2022 05:00 ET
|
Green Nexus
HOLLYWOOD, Calif., Feb. 08, 2022 (GLOBE NEWSWIRE) -- Green Nexus is the first authorized United States distributor of Barneys Farm seeds, one of the world's most recognized, awarded, and reputable...
CORBUS PHARMACEUTICALS ANNOUNCES ADJOURNMENT OF ANNUAL MEETING
May 19, 2021 09:20 ET
|
Corbus Pharmaceuticals Holdings, Inc.
Norwood, MA, May 19, 2021 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage drug development company pioneering transformative...
More Than 100 Speakers Present at Whole Plant Expo
October 28, 2020 10:41 ET
|
Whole Plant Expo
PORTLAND, Ore., Oct. 28, 2020 (GLOBE NEWSWIRE) -- Whole Plant Expo™ (www.wholeplantexpo.com) today previewed the second half of this groundbreaking online event. More than 100 expert speakers –...
New Comprehensive CBD Alternative from Life Extension®, Introducing Endocannabinoid Support, without THC or Hemp
October 13, 2020 10:15 ET
|
Life Extension
Fort Lauderdale, FL, Oct. 13, 2020 (GLOBE NEWSWIRE) -- With the increasing popularity of CBD, there’s lots of “buzz” around endocannabinoids these days -- but what are they? Your endocannabinoid...
Emerald Health Therapeutics Announces Internal Reorganization
October 30, 2019 07:00 ET
|
Emerald Health Therapeutics Inc.
VANCOUVER, British Columbia, Oct. 30, 2019 (GLOBE NEWSWIRE) -- Emerald Health Therapeutics, Inc. (“Emerald”) (TSXV: EMH; OTCQX: EMHTF) has announced an internal reorganization including the...
Corbus Pharmaceuticals Reports 2019 Second Quarter Financial Results and Provides Clinical and Corporate Updates
August 08, 2019 07:05 ET
|
Corbus Pharmaceuticals Holdings, Inc.
Clinical development of lenabasum on target for 2020 data readouts in lead indications systemic sclerosis and cystic fibrosis; diseases affect ~270,000 people total in U.S., EU and Japan CRB-4001 on...
Emerald Health Therapeutics Closes Emerald Health Naturals Joint Venture
January 10, 2019 07:00 ET
|
Emerald Health Therapeutics Inc.
VICTORIA, British Columbia, Jan. 10, 2019 (GLOBE NEWSWIRE) -- Emerald Health Therapeutics, Inc. (“Emerald”) (TSXV:EMH; OTCQX:EMHTF) is pleased to announce that, further to its news releases dated...
Emerald Joint Venture Receives Licenses from Health Canada to Sell Proprietary Products Supporting the Endocannabinoid System
December 04, 2018 07:00 ET
|
Emerald Health Therapeutics Inc.
Endo Brain recently awarded 2018 SupplySide Editor’s Choice Award for Brain Health Planned mid-2019 product launch will open natural health product, grocery, and pharmacy store channels to Emerald...
Emerald Health Therapeutics Receives TSX Venture Conditional Approval of Emerald Health Naturals Joint Venture
November 19, 2018 07:00 ET
|
Emerald Health Therapeutics Inc.
Joint venture to distribute endocannabinoid-supporting products to Canadian natural health product stores and pharmacies VICTORIA, British Columbia, Nov. 19, 2018 (GLOBE NEWSWIRE) -- Emerald...